Immune checkpoint blockade therapy represented by PD-1/PD-L1 inhibition is the most promising paradigm for the application of these concepts to therapeutic strategies [7,8], showing a favorable safety profile and reliable clinical benefit in advanced NSCLC patients [9,10,11,12]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.